SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

THIOGUANINE TABLETS

of the mixture

Registration number

Synonyms THIOGUANIN GSK TABLETTEN 40 MG * TABLOID BRAND THIOGUANINE TABLETS 40 MG *

TABLOID COMPRIMIDOS * TIOGUANINE TABLET 40 MG * TIOGUANINA WELLCOME COMPRIMIDOS * LANVIS TABLETS 40 MG * THIOGUANINE, FORMULATED PRODUCT

Issue date 10-September-2014

Version number

Revision date 10-September-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information None.

2.3. Other hazards Caution - Potent pharmaceutical agent. See section 11 for additional information on health

hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: THIOGUANINE TABLETS

General information

CAS-No. / EC No. REACH Registration No. INDEX No. **Chemical name** % **Notes**

THIOGUANINE 10 - < 20 154-42-7 M=100 2058272

Classification: **DSD:** Carc. Cat. 3;R40, Muta. Cat. 3;R68, Repr. Cat. 2;R60-61, Xn;R22, N;R50/53

Acute Tox. 4;H302, Muta. 2;H341, Carc. 2;H351, Repr. 1B;H360, Aquatic

Acute 1;H400, Aquatic Chronic 1;H410

Starch 5 - < 10 9005-25-8

232-679-6

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE 557-04-0 < 0.2

209-150-3

Classification: DSD: -

CLP: -

Other components below reportable levels 70 - < 80

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

The full text for all R- and H-phrases is displayed in section 16. **Composition comments**

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

In case of accident by inhalation: remove casualty to fresh air and keep at rest. Move to fresh air. If Inhalation

> breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an

inhalation hazard.

Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Skin contact

Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large Ingestion

amount does occur, call a poison control centre immediately. Do not induce vomiting without

medical advice.

4.2. Most important symptoms and effects, both acute and

delayed

Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash,

hives, itching).

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For

additional guidance, refer to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

None known.

media

Unsuitable extinguishing media

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

Foam. Dry chemical powder. Carbon dioxide (CO2). Water.

5.3. Advice for firefighters

Special protective equipment for firefighters

Material name: THIOGUANINE TABLETS

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures

Use water spray to cool unopened containers.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency

personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

SDS.

6.2. Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up

Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or

confined areas. Following product recovery, flush area with water.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe

Avoid prolonged exposure.

handling

7.2. Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store away from incompatible materials (see Section 10

of the SDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

CCV

Occupational exposure limits

Components	Туре	Value	Note
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
THIOGUANINE (CAS 154-42-7)	8 HR TWA	10 mcg/m3	
	OHC	4	Carcinogen
		4	Reproductive hazard
UK. EH40 Workplace Exposure Li	imits (WELs)		
Components	Туре	Value	Form
Starch (CAS 9005-25-8)	TWA	4 mg/m3	Respirable.
		10 mg/m3	Inhalable

Biological limit values

No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Not available.

Derived no-effect level (DNEL)

Not available.

Predicted no effect concentrations (PNECs)

Not available.

8.2. Exposure controls

Appropriate engineering

General ventilation normally adequate.

controls

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

Eye/face protection Not normally needed. If contact is likely, safety glasses with side shields are recommended. (eg.

EN 166)

Skin protection

Material name: THIOGUANINE TABLETS

- Hand protection Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select

suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min

permeation time).

- Other Not normally needed. Wear suitable protective clothing as protection against splashing or

contamination. (EN 14605 for splashes, EN ISO 13982 for dust)

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg.

EN 14387).

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations

Contain spills and prevent releases and observe national regulations on emissions. Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid. Tablet. **Form** Colour Not available. Not available. Odour Not available. **Odour threshold** Not available. pН Not available. Melting point/freezing point Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Vapour pressureNot available.Vapour densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Not available.

Solubility (other) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.Explosive propertiesNot available.Oxidizing propertiesNot available.

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Not available

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoidContact with incompatible materials.

10.5. Incompatible materials Peroxides. Phenols.

10.6. Hazardous Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

decomposition products

Material name: THIOGUANINE TABLETS

SECTION 11: Toxicological information

General information This preparation contains ingredient(s) with the following activity: a nucleoside analogue.

Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

May be harmful if swallowed. Health injuries are not known or expected under normal use. Ingestion

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Health injuries are not known or expected under normal use. Health injuries are not known or expected under normal use. Eye contact

Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash, **Symptoms**

hives, itching).

11.1. Information on toxicological effects

Acute toxicity May be harmful if swallowed.

Test results Components **Species**

MAGNESIUM STEARATE (CAS 557-04-0)

Acute

Oral

LD50 Rat > 2000 mg/kg

THIOGUANINE (CAS 154-42-7)

Acute

Oral

LD50 Rat 650 mg/kg

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

THIOGUANINE Acute dermal irritation; OECD 404, Primary Irritation Index: 0

> Result: negative Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE

Serious eye damage/eye

irritation Eve

Health injuries are not known or expected under normal use.

THIOGUANINE Acute ocular irritation; OECD 405, Kay and Calandra score =

4; maximum group mean score = 9.3

Result: Mild irritant Species: Rabbit IRE Assay

Result: Negative; not likely to be a severe irritant

Eve / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory sensitisation Knowledge about health hazard is incomplete.

Skin sensitisation Health injuries are not known or expected under normal use.

Possible human mutagen. Germ cell mutagenicity

Mutagenicity

Material name: THIOGUANINE TABLETS

THIOGUANINE Ames Assay, GLP assay

Result: negative

Chromosomal Aberration Assay In Vitro, CHO cells,

Literature data Result: positive

Dominant lethal assay, Literature data

Result: positive Species: Mouse GreenScreen Assay Result: positive

Known or probable human carcinogen. Contains a component listed as a carcinogen by: (GSK) Carcinogenicity

No components are listed as carcinogens by: (IARC); (NTP); (US OSHA); (EU).

THIOGUANINE SAR / QSAR

Result: Plausible structural alert identified

Possible reproductive hazard. Possible risk of toxicity in developing human offspring. Reproductive toxicity

Specific target organ toxicity -

single exposure

Not established.

0----

Specific target organ toxicity -

repeated exposure

THIOGUANINE

May cause damage to organs.

Repeat dose non-clinical studies: clinical observation

Organ: bone marrow; liver; immune system

Aspiration hazard Not likely, due to the form of the product.

Mixture versus substance

information

No information available.

Other information Caution - Pharmaceutical agent.

SECTION 12: Ecological information

12.1. ToxicityContains a substance which causes risk of hazardous effects to the environment. The product

contains a substance which may cause long-term adverse effects in the environment.

Components		Species	Test results
MAGNESIUM STEARATE ((CAS 557-04-0)		
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
THIOGUANINE (CAS 154-4	12-7)		
Acute			
	IC50	Activated sludge	> 1000 mg/l, 3 hours
Aquatic			
Acute			
Algae	EC50	Green algae (Scenedesmus subspicatus)	0.0034 mg/l, 72 hours Static test
	NOEC	Green algae (Scenedesmus subspicatus)	0.0005 mg/l, 72 hours Static test
Crustacea	EC50	Water flea (Daphnia magna)	16.5 mg/l, 48 hours

^{*} Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

•

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

THIOGUANINE 62 Days Measured, Deionized Water

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

THIOGUANINE 0 %, 28 days Modified MITI (II) Test., Activated sludge

68 %, 28 days Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

THIOGUANINE -0.07

Bioconcentration factor (BCF)

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general

Volatility

Henry's law

THIOGUANINE 0 atm m^3/mol Calculated, 25 C

12.5. Results of PBT

and vPvB assessment

Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste codeThe Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose in

accordance with all applicable regulations.

Special precautionsDispose in accordance with all applicable regulations.

SECTION 14: Transport information

General Classifications are for the material when offered for transport as fully regulated. Depending on

the specific transport details (Ship-From/Ship To locations, quantities being shipped, type of packaging and mode of transport) it may be possible to ship this material in a manner other than fully regulated. (One example is IATA Limited or Excepted Quantity. There are others.) Be sure to review all regulatory agency packaging instructions and special provisions, referenced in this

section, to identify options applicable to the specifics of your shipment.

ADR

14.1. UN number UN3077

14.2. UN proper shipping

name

Environmentally hazardous substances, solid, n.o.s. (THIOGUANINE TABLETS)

14.3. Transport hazard class(es)

Class 9
Subsidiary risk Label(s) 9

Hazard No. (ADR) Not available.

Tunnel code Not available.

14.4. Packing group III
14.5. Environmental hazards Yes

14.6. Special precautions Not available.

for user

IATA

14.1. UN number UN3077

14.2. UN proper shipping Environmentally hazardous substance, solid, n.o.s. (THIOGUANINE TABLETS)

name

14.3. Transport hazard 9

class(es)

Subsidiary class(es) 14.4. Packing group III
Labels required 9
14.5. Environmental hazards No.
ERG Code 9L

14.6. Special precautions

for user

Not available.

Other information

Cargo aircraft only

Allowed.

Additional Information:

Material name: THIOGUANINE TABLETS

Passenger & cargo Allowed.

IMDG

14.1. UN number UN3077

14.2. UN proper shipping ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (THIOGUANINE TABLETS)

name

14.3. Transport hazard class(es)

Class 9
Subsidiary risk Label(s) 9
14.4. Packing group III
14.5. Environmental hazards

Marine pollutantYesEmSF-A, S-F14.6. Special precautionsNot available.

for user

14.7. Transport in bulk Not applicable.

according to Annex II of

MARPOL73/78 and the IBC Code

ADR; IATA; IMDG



Marine pollutant



General information

Classifications are for the material when offered for transport as fully regulated. Depending on the specific transport details (Ship-From/Ship To locations, quantities being shipped, type of packaging and mode of transport) it may be possible to ship this material in a manner other than fully regulated. (One example is IATA Limited or Excepted Quantity. There are others.) Be sure to review all regulatory agency packaging instructions and special provisions, referenced in this section, to identify options applicable to the specifics of your shipment.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006. Pregnant women should not work with the product, if there is the least risk of exposure.

National regulations Young people under 18 years old are not allowed to work with this product according to the EU

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements

under Sections 2 to 15

R22 Harmful if swallowed.

R40 Limited evidence of a carcinogenic effect.

R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R60 May impair fertility.

R61 May cause harm to the unborn child. R68 Possible risk of irreversible effects.

H302 Harmful if swallowed.

H341 Suspected of causing genetic defects.

H351 Suspected of causing cancer.

H360 May damage fertility or the unborn child.

H400 Very toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.

Revision information Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Physical & Chemical Properties: Ecological Information: Mobility

Transport Information: Material Transportation Information

Regulatory Information: United States

GHS: Classification

Material name: THIOGUANINE TABLETS

Training information Disclaimer

Follow training instructions when handling this material.

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Material name: THIOGUANINE TABLETS

110579 Version No.: 14 Revision date: 10-September-2014 Issue date: 10-September-2014